News briefing: New senescent cell play launches with $12M; Junshi leads Series C+ infusion for Chinese synthetic lethality player
The idea of targeting senescent cells to treat age-related diseases is continuing to gather steam, and Khosla Ventures is helping get the latest play going with a $12 million seed round.
Rubedo Life Sciences is focusing its initial efforts on respiratory diseases such as idiopathic pulmonary fibrosis and obstructive pulmonary disease, with preclinical programs in oncology, neurodegenerative conditions, skeletal muscle disorders and others to follow.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.